{
    "id": "dbpedia_4251_3",
    "rank": 97,
    "data": {
        "url": "https://nap.nationalacademies.org/read/18277/chapter/41",
        "read_more_link": "",
        "language": "en",
        "title": "The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions",
        "top_image": "https://nap.nationalacademies.org/cover/18277/450",
        "meta_img": "https://nap.nationalacademies.org/cover/18277/450",
        "images": [
            "https://nap.nationalacademies.org/read/img/openbook-header-print.png",
            "https://nap.nationalacademies.org/cover/18277/450",
            "https://nap.nationalacademies.org/images/hdr/logo-nasem-wht-lg.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Read chapter Appendix E.5: Rusnano and Other Russian Investors: In the fall of 2010, the U.S. National Academies (consisting of the National Academy of Sc...",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "The National Academies Press",
        "canonical_link": "https://nap.nationalacademies.org/read/18277/chapter/41",
        "text": "Appendix E.5\n\nRusnano and Other Russian Investors\n\nRusnano is a Russian state-owned equity and venture capital fund. It was set up in 2007 as a state-owned corporation with an investment level of $9 billion, but reorganized in 2011 as a joint-stock company. It has a mandate to develop the nanotech industry in Russia by investing in companies in order to develop and commercialize nanotech-based products in Russia with the goal of nanotech sales reaching $40 billion by 2015. As of June 2012, approximately 20 percent of the funds were to be directed to projects in the life sciences.\n\nInvestments and commitments by Rusnano and other Russian investors in biotech activities have been announced as follows:\n\n1: Investments in Venture Funds by Russian Organizations:\n\nVenture Fund/Location/Investor/Fund Value\n\nDomain Associates/U.S./Rusnano (50%)/$760 million\n\nBurrill Capital Fund IV/U.S./Rusnano (40%)/$500 million\n\nMaxwell Biotech/U.S.-Russia/Russian Venture Company/$100 million\n\nRVC Intrafund/Russia/Russian Venture Company/$68 million\n\nRVC Biofund/Russian Venture Company/$50 million\n\n2: Russian Investments in Companies:\n\nCompany/Location/Investor/Commitment\n\nProBonoBil U.K./Russia/Rusnano/$300 million\n\nNearmedic Plus/Russia/Rusnano/$41 million\n\nMagnisense/France/Rusnano/$38 million\n\nSynBio/Russia/Rusnano/$31 million\n\nPanacela Laboratories/U.S./Rusnano/$26 million\n\nBIND Biosciences/U.S./Rusnano/$25 million\n\nSelecta Biosciences/U.S./Rusnano/$25 million\n\nBIOptics/U.S./Rusnano/$5 million\n\nCardioNova/Russia/Maxwell Biotech/$1–5 million\n\nHepatera/Russia/Maxwell Biotech/$1–5 million\n\nInfectex/Russia/Maxwell Biotech/$1–5 million\n\nMetaMax/Russia/Maxwell Biotech/$1–5 million\n\nEXAMPLES OF ACTIVITIES OF SPECIAL INTEREST TO RUSNANO:\n\nBIND Biosciences (Cambridge, Mass.): Development in Russia of therapeutic nanoparticles for use in addressing solid tumors, inflammatory, and cardiovascular diseases. http://www.bindbio.com/content/pages/company/aboutrussia.jsp\n\nSelecta Biosciences (Watertown, Mass.): Development in Russia of synthetic vaccine nanoparticles that encapsulate adjuvant and either a T-cell epitope or allergen in a polylactic acid-co-glycolic acid core surrounded by a lipid monolayer and a PEG shell decorated with a B-cell epitope.\n\nPanacela Labs (Buffalo, N.Y.): A 4-year venture between Rusnano ($9 million) and Cleveland BioLabs ($3 million) for an oncology subsidiary.\n\nBiOptix Diagnostics (Boulder, Colo.): Development of a surface plasmon-enhanced interferometer-detector for label-free bioassays.\n\nhttp://cen.acs.org/articles/90/i16/Russian-Investors-Bankroll-biotech.html?h=1167136384. Accessed July 7, 2012."
    }
}